Perrigo's 'Inversion' Of Flonase Trademark Cuts Too Close For Glaxo's Market Share Comfort
This article was originally published in The Tan Sheet & The Rose Sheet
Glaxo says it distributed more than $330m in Flonase Allergy Relief in 2015, its first year available as the second-in-category corticosteroid nasal spray, but argues that Nasoflow, Perrigo's brand for a generic equivalent, unfairly will encroach on its sales and market share.
You may also be interested in...
FDA grants Glaxo market exclusivity for OTC as the first OTC fluticasone product, but with a label carve-out that limits exclusivity to the indication of “OTC use for temporary relief of ocular symptoms due to hay fever or other upper respiratory allergies.”
FDA threatens enforcement action against two firms selling red yeast rice supplements adulterated with lovastatin - the active ingredient in Merck's Rx cholesterol-lowering drug Mevacor. Consumers should not purchase or consume Swanson Healthcare Products' Red Yeast Rice and Red Yeast Rice/Policosonal Complex or Sunburst Biorganics' Cholestrix since FDA testing revealed the presence of the statin, which can cause harmful side-effects such as muscle weakness and kidney issues and may interact with other medications, FDA announces Aug. 9. The agency determined the adulterated supplements are unapproved new drugs, sent warning letters to the companies marketing the products and threatens to employ enforcement actions, such as seizure of illegal products and criminal prosecution if the companies fail to resolve the violations immediately, according to the warning letters. In January 2005, Source Naturals received a courtesy letter from FDA for the same problem (1"The Tan Sheet" Jan. 24, 2005, In Brief)...
Senate votes down Illinois Democrat’s proposal to amend stopgap appropriations bill with language calling for establishing mandatory products listing program in FDA. But proposal to give FDA MPL authority likely will return in Congress, says Natural Products Association.